ClinicalTrials.gg
Status unknownNCT04616859ENERGYBINGEUpdated Nov 9, 2020

Binge Drinking of Alcohol Mixed With Energy Drinks

An interventional study of Alcohol and Energy Drink (AmED) and Alcohol and Energy drink Placebo in Healthy and Alcohol Drinking, sponsored by Fundació Institut Germans Trias i Pujol. Status unknown at 1 site in Spain. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by Fundació Institut Germans Trias i Pujol · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The purpose of the study is to assess the relevance of gender in the acute effects (subjective, physiological and driving-related skills) observed after controlled administration of alcohol in a binge-drinking pattern mixed with energy drinks (AmED)

Read the detailed description

Consumption of alcohol mixed with energy drinks (AmED) has increased mainly among young people. Energy drinks (ED) are usually combined with alcohol with the intention of counteracting its effects. However, most studies have not shown a reduction in drunkenness and consumption is related with engagement of risk-taking behaviours like driving under alcohol effects. It is already known that alcohol concentrations and effects are higher in women than in men even after adjusting dose by weight.

The relevance of gender in the acute effects of alcohol associated with ED consumed in a binge-drinking pattern has been poorly studied. A randomized clinical trial will be conducted in healthy volunteers (1:1) and four treatment conditions will be administered: alcohol+ED, alcohol+placebo of ED, placebo of alcohol+ED and placebo of alcohol+placebo of ED. Subjective and physiological effects, driving related skills, and alcohol and caffeine concentrations will be measured along an 8-hours period. A pilot study has been conducted with the first 6 volunteers to select the alcohol doses. In the definitive study 70 g of alcohol in men and 55 g in women will be used.

02

Conditions studied

  • Healthy
  • Alcohol Drinking

Browse trials for

Keywords

  • alcohol binge drinking
  • alcohol
  • energy drinks
  • pharmacokinetics
  • caffeine
  • gender
03

In context

Alcohol Drinking

701 studies on the registry are indexed under Alcohol Drinking; 133 are open to participants now.

This study's planned enrollment of 32 is below the median of 122 across 607 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

Fundació Institut Germans Trias i Pujol is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females between 18-40 years old, weight between 50 and 100 kg and (BMI=weight/height²) between 20-28 kg/m². Lower or higher BMIs will be allowed, if the researchers considered that do not suppose a risk to the subjects and do not interfere with the objectives of the study.
  2. Recreational alcohol consumption in form of occasional binge-drinking (≥1 episode / month) and at least consumption of 1 unit (10 g, "standard" drink - one alcoholic drink equivalent) per day or its equivalent over the whole week [7 units, 70 g)]) and having experienced drunkenness several times
  3. Regular consumption of beverages containing methylxanthines at least 7 per week (coffee, tea, chocolate, cola soda, energy drinks). Consumption of energy drinks at least once.
  4. Understand and accept the study's procedures and sign an form.
  5. No evidence of somatic or psychiatric disorders as per past medical history and physical examination.
  6. The and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not , are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.

Exclusion criteria

Exclusion Criteria:

  1. Not fill the inclusion criteria.
  2. Pathological history or evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of drugs or symptoms suggestive of drug-induced gastrointestinal irritation.
  3. Present history of a substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (), except for nicotine. Past history of mild substance use disorder (corresponding to substance abuse according to DSM-IV) could be included.
  4. Previous or actual psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs.
  5. Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
  6. Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial.
  7. Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks. Asian subjects with no intolerance or no serious adverse reactions to alcohol could be included.
  8. Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session.
  9. Smokers of >5 cigarettes/day
  10. Consumption of >20 g/day of alcohol (females) or of >40 g/day (males)
  11. Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study.
  12. Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  13. Subjects with positive serology to , C or .
  14. Pregnant, breastfeeding women and those using hormonal ,. Those not using an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy).
  15. Women with amenorrhea or suffering severe premenstrual syndrome.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Alcohol and Energy Drink (AmED)

    The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml

    Dietary Supplement: Alcohol and Energy Drink (AmED)

  • Active comparator
    Alcohol and Energy drink Placebo

    The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)

    Dietary Supplement: Alcohol and Energy drink Placebo

  • Active comparator
    Alcohol placebo and Energy drink

    The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL

    Dietary Supplement: Alcohol placebo and Energy drink

  • Placebo comparator
    Alcohol placebo and Energy drink placebo

    The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL

    Dietary Supplement: Alcohol placebo and energy drink placebo

Interventions

  • Dietary supplementAlcohol and Energy Drink (AmED)

    Multiple oral dose of alcohol mixed with ED

  • Dietary supplementAlcohol and Energy drink Placebo

    Multiple oral dose of alcohol mixed with ED placebo (soft drink)

  • Dietary supplementAlcohol placebo and Energy drink

    Multiple oral dose of alcohol placebo (water) mixed with ED

  • Dietary supplementAlcohol placebo and energy drink placebo

    Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)

06

What researchers measure

Primary outcomes

  1. Change in subjective effects measured with Biphasic alcohol effects scale (BAES)

    Subjective effects of alcohol will be measured using Biphasic alcohol effects scale (0-70 points). Higher scores mean worse outcome. Obtained baseline and 1, 1.30, 2, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  2. Change in psychomotor vigilance task (PVT)

    Test will be performed using a specific software. Mean latency will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.

    Time frame: From baseline to 6 hours after administration

Secondary outcomes

  1. Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations

    Calculation of AUC of ethanol blood concentrations. Obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  2. Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations

    Obtained baseline and 0.15, 0.30 , 0.45, 1, 1.15,1.30, 1.45, 2, 2.15, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  3. Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations

    Calculation of AUC of caffeine concentrations obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  4. Maximum concentration (Cmax) of ethanol in blood

    Maximum concentration (Cmax) of ethanol in blood

    Time frame: From baseline to 8 hours after administration

  5. Maximum concentration (Cmax) of caffeine in plasma

    Maximum concentration (Cmax) of caffeine in plasma

    Time frame: From baseline to 8 hours after administration

  6. Time to reach maximum concentration (tmax) of ethanol in blood

    Time to reach maximum concentration (tmax) of ethanol in blood

    Time frame: From baseline to 8 hours after administration

  7. Time to reach maximum concentration (tmax) of ethanol in breath air

    Time to reach maximum concentration (tmax) of ethanol in breath air

    Time frame: From baseline to 8 hours after administration

  8. Time to reach maximum concentration (tmax) of caffeine in plasma

    Time to reach maximum concentration (tmax) of caffeine in plasma

    Time frame: From baseline to 8 hours after administration

  9. Area under the concentration-time curve (AUC 0-8h) of taurine plasma concentrations

    Calculation of AUC of taurine concentrations obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration

    Time frame: From baseline to 8 hours after administration

  10. Maximum concentration (Cmax) of taurine plasma concentrations

    Maximum concentration (Cmax) of taurine plasma concentrations

    Time frame: From baseline to 8 hours after administration

  11. Time to reach maximum concentration (tmax) of taurine plasma concentrations

    Time to reach maximum concentration (tmax) of taurine plasma concentrations

    Time frame: From baseline to 8 hours after administration

  12. Change in drunkenness feeling

    Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  13. Change in dizziness feeling

    Dizziness will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  14. Change in drowsiness feeling

    Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  15. Change in palpitations reported by the participant

    Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  16. Change in anxiety feeling

    Anxiety will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  17. Change in headache

    Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  18. Change in ability and predisposition to drive in certain situations

    Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.30, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  19. Desire to keep drinking

    Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.30 hours.

    Time frame: At 1.30 hours

  20. Change in subjective effects measured with Addiction Research Center Inventory (ARCI)

    Obtained baseline and 1, 1.45, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  21. Change in blood pressure

    Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  22. Change in heart rate

    Heart rate (beats/min) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  23. Change in oral temperature

    Oral temperature (ºC) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

    Time frame: From baseline to 8 hours after administration

  24. Change in Maddox Wing score (MW)

    Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.30, 4 and 6-h after administration.

    Time frame: From baseline to 6 hours after administration

  25. Beverage identification

    Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration

    Time frame: 8 hours after administration

  26. Change in tracking test performance

    Test will be performed using a computer program. Total time outside the road and number of errors will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.

    Time frame: From baseline to 6 hours after administration

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitari Germans Trias i Pujol-Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Clara Pérez-Mañá, MD, PhD · Contactcperezm.mn.ics@gencat.cat · +34 934978865
    • Magi Farré, MD,PhD · Contactmfarre.germanstrias@gencat.cat · +34 934978865
    • Clara Pérez-Mañá, MD, PhD · Principal investigator
    • Magí Farré, MD, PhD · Sub investigator
    • Esther Papaseit, MD, PhD · Sub investigator
    • Ana Maria Barriocanal, MD, PhD · Sub investigator
    • Soraya Martin, RN · Sub investigator
    • Alexandra Vila, RN · Sub investigator
    • Olga Hladun, MD · Sub investigator
    • Ana Pilar Pérez, MD · Sub investigator
    • Melani Nuñez, MD · Sub investigator
    • Lourdes Poyatos, BS · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04616859
Lead sponsor
Fundació Institut Germans Trias i Pujol
Collaborators
Germans Trias i Pujol Hospital
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Oct 8, 2020
Primary completion
Dec 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
Nov 9, 2020

Study contacts

Clara Pérez-Mañá, MD,PhD
Contact
cperezm.mn.ics@gencat.cat
+34 93 497 88 65
Magi Farré, MD, PhD
Contact
mfarre.germanstrias@gencat.cat
+34 93 497 88 65
Clara Pérez-Mañá, MD, PhD
principal investigator · Hospital Universitari Germans Trias i Pujol-IGTP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion